Cell Therapy Manufacturing & Gene Therapy Congress

Regulatory approvals and innovation drives: Cell therapies come of age

By Dan Stanton contact

- Last updated on GMT

Regulatory approvals and innovation drives: Cell therapies come of age

Related tags: Cell therapy manufacturing, Gene, Cell therapy manufacturing & gene therapy congress

Cell therapies have reached their 'teenage years' and must now overcome processing efficiencies and quality struggles, say industry delegates.

At today’s Cell Therapy Manufacturing & Gene Therapy Congress, delegates declared personalised cell and gene-based medicines are rapidly approaching maturity but still struggle with commercial production processes.

“The cell therapy field is in its teenage years,”​ Miguel Forte, CEO of Zelluna Immunotherapy, told a packed room in Amsterdam, The Netherlands. “But I have five children so I know very well how difficult those teenage years are. There is a lot of innovation and there’s a lot of value being brought, but there is still a struggle with quality.”

Forte said he moved into the space in its infancy, over a decade ago, when such therapies were deemed as “cute things,”​ but regulatory approvals now show the commercial reality of cell and gene therapies.

GSK’s autologous CD34+ enriched cell fraction Strimvelis was approved in the EU in 2016​, for example, while the last few months have seen the US approve the first two chimeric antigen receptor (CAR) T-cell therapies: Novartis’ Kymriah​ (tisagenlecleucel) and Kite/Gilead’s Yescarta​ (axicabtagene ciloleucel).

And as it enters adolescence, the space is becoming more competitive, he continued. “Competition is great, it’s a huge driver for everything.”​ He explained the recent commercial successes have validated the manufacturing process, companies are now competing to make more efficient and productive platforms.

“It’s cashing in on established processes and being able to on to new approaches,” ​he said, adding there is now constant discussion among both vendors and end-users at developing technology advances while working from a common manufacturing background.

In follow up presentations, delegates from both successful CAR-T cell developers, Kite and Novartis, agreed with Forte that the sector is moving towards maturity. Lonza’s associate director of commercial development for cell therapies Nina Bauer added from the CMO’s point of view the sector is perhaps further along (“in its late-teenage stage”​) but “is in a space where manufacturing and commercialisation challenges need to be looked at.”

Related news

Show more

Related products

show more

CadenceILC_610x343

Inline concentration improves process economics

Pall Biotech | 15-Jun-2018 | Case Study

Would you like to enhance your downstream process, increase production capacity and reduce costs? This case study application note demonstrates how implementing...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 21-May-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...

Related suppliers

Follow us

Products

View more